With this agreement, Handok Biotech will exclusively represent BioIVT’s comprehensive portfolio of biofluids, tissues, cell products, media, and subcellular fractions/enzymes in South Korea.

South Korea had been navigating six months of political turbulence following former President Yoon Suk-Yeol's brief ...

today announced an exclusive commercial agreement with Handok Biotech Co. LTD., which will allow Handok to offer researchers in South Korea access to a wider range of high-quality, innovative ...

South Korea has designated life sciences and biotechnology as priority areas for growth and leadership. The country is experiencing rapid growth in biotechnology thanks to continuous public and ...

Four biotech companies from South Korea announced new or planned financings mid-June, including GC Genome Corp. Rznomics Inc., G2Gbio Inc. and Mezzion Pharma Co. Ltd. Six major mid-June deals included ...

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, announced an exclusive commercial agreement with Handok Biotech Co. LTD., which will allow ...

CHA Biotech announced on the 28th that its early ovarian failure treatment ‘CBT210-POI’ has been confirmed for safety and tolerability in a phase 1 clinical trial in South Korea. Early ovarian ...

Addressing the mismatch between education and job market needs in India, highlighting the importance of employability over ...

A South Korean biotechnology company has won a patent ... violated the composition patent of its Prevnar 13 vaccine. South Korea's Supreme Court recently upheld a lower court's decision that ...